Adjuvant Imatinib Maintenance for 6 Years Lowers Recurrence Risk in High-Risk GIST
Patients with gastrointestinal stromal tumors (GIST) at a high risk of recurrence who underwent 6 years of adjuvant imatinib (Gleevec) after resection—vs the standard 3-year duration—experienced a significant reduction in the risk of recurrence or death …